Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -8.4% | 25.9% | -25.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 70.6% | 70.8% | 67.5% | 72.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -47.8% | -46.4% | -81.4% | -70% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -58.6% | -57.3% | -102.3% | -79.8% |
| EPS Diluted | -0.34 | -0.36 | -0.58 | -0.62 |
| % Growth | 5.6% | 37.9% | 6.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |